Results 211 to 220 of about 5,296,642 (245)

Fibroblast Activation Protein Inhibitor PET Imaging in Head and Neck Cancer

PET Clinics, 2023
68Ga-fibroblast activation protein inhibitor (FAPI)-PET is highly promising for head and neck cancers including oral squamous cell carcinomas, hypopharynx carcinomas, adenoid cystic carcinomas, thyroid cancer, and cervical cancer of unknown primary. For oral squamous cell carcinomas, hypopharynx carcinomas, and adenoid cystic carcinomas, 68Ga-FAPI-PET ...
openaire   +2 more sources

Fibroblast Activation Protein Inhibitor Theranostics in Sarcoma

Clinical Nuclear Medicine
Sarcomas are rare and heterogeneous cancers arising from mesenchymal tissues, presenting diagnostic and therapeutic challenges. Fibroblast activation protein (FAP), overexpressed in the tumor microenvironment of many sarcomas, has emerged as a promising theranostic target.
Esmail Jafari, Malik E. Juweid, Narges Jokar, Nader Shakibazad, Seyed Javad Rekabpour, Majid Assadi   +5 more
openaire   +2 more sources

Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations.

PET clinics, 2023
Fibroblast activation protein (FAP) was first reported in 1986. However, FAP is not expressed in normal fibroblasts, normal or malignant epithelial cells, or the stroma of benign epithelial tumors. FAP is a cell membrane-bound serine peptidase overexpressed on the surface of cancer-associated fibroblasts and, as such, is a novel target for molecular ...
Kazuko, Kaneda-Nakashima, Yoshifumi, Shirakami, Yuichiro, Kadonaga, Tadashi, Watabe   +3 more
openaire   +1 more source

Applications of Fibroblast Activation Protein Inhibitor-PET in Interventional Oncology

PET Clinics
Molecular imaging-guided techniques increase precision in surgical procedure and reduce postinterventional morbidity. Fibroblast activation protein (FAP) ligands may contribute to the superior preoperative assessment compared with conventional radionuclides due to its higher sensitivity and tumor delineation in epithelial malignancies. Wide spectrum of
Yuriko, Mori, Emil, Novruzov, Frederik L, Giesel, Abass, Alavi   +3 more
openaire   +2 more sources

Fibroblast activation protein inhibitor PET for monitoring fibrotic diseases

Ugeskrift for Læger
Fibroblast activation protein inhibitor (FAPI) PET was initially developed for cancer diagnostics; however, studies suggest that FAPI PET is a promising modality in various fibrotic diseases, including interstitial lung disease, fibrotic myocardial diseases, and rheumatic diseases such as rheumatoid arthritis, IgG4-related disease, and systemic ...
Rikke Helin, Johnsen, Katja Bjerregaard, Christensen, Saher B, Shaker, Jann, Mortensen, Christoffer Tandrup, Nielsen   +4 more
openaire   +2 more sources

Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission

Rheumatology
AbstractObjectivesEpigenetically modified fibroblasts contribute to chronicity in inflammatory diseases. Reasons for the relapsing character of large vessel vasculitis (LVV) remain obscure, including the role of fibroblasts, in part due to limited access to biopsies of involved tissue.68Ga FAPI-46 (FAPI)-PET/CT detects activated fibroblasts in vivo. In
Manuel Röhrich, Juan J Rosales, Jorge Hoppner, Peter Kvacskay, Norbert Blank, Lisa Loi, Daniel Paech, Mathias Schreckenberger, Frederik Giesel, Hans Ulrich Kauczor, Hanns Martin Lorenz, Uwe Haberkorn, Wolfgang Merkt   +12 more
openaire   +2 more sources

Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold

Med. Chem. Commun., 2014
The first selective, non-peptide derived inhibitors of FAP are presented.
Jansen, Koen, De Winter, Hans, Heirbaut, Leen, Cheng, Jonathan D., Joossens, Jurgen, Lambeir, Anne-Marie, De Meester, Ingrid, Augustyns, Koen, van der Veken, Pieter   +8 more
openaire   +2 more sources

Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation.

PET clinics, 2023
Fibroblast activation protein (FAP)-targeted radioligand therapy offers a possibility of a novel cancer therapeutic strategy, aiming at tumor stroma1. Early clinical translations of FAP-tracers occurred as early as in the 1990s using antibodies, without substantial achievement further than the clinical phase II trial.
Yuriko, Mori, Clemens, Kratochwil, Uwe, Haberkorn, Frederik L, Giesel   +3 more
openaire   +1 more source

Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma.

PET clinics, 2023
The theranostic use of fibroblast activation protein inhibitors (FAPIs) is a novel approach in oncology. Sarcomas are a heterogenous group of rare malignant tumors. Prognosis remains poor in advanced/metastatic disease due to limited therapeutic options.
Rainer, Hamacher, Helena, Lanzafame, Ilektra A, Mavroeidi, Kim M, Pabst, Lukas, Kessler, Phyllis F, Cheung, Sebastian, Bauer, Ken, Herrmann, Hans-Ulrich, Schildhaus, Jens T, Siveke, Wolfgang P, Fendler   +10 more
openaire   +1 more source

Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with α-ketoamide warheads

European Journal of Medicinal Chemistry, 2021
Pavel Šácha, Tereza Ormsby, Adéla Šimková   +2 more
exaly